CAS 865792-18-3
:6-[4-(1-Cicloesil-1H-tetrazol-5-il)butossi]-1-[4-(1-cicloesil-1H-tetrazol-5-il)butil]-3,4-diidro-2(1H)-chinolinone
- 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one
- 6-(4(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-1-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butyl)-3,4-dihydroquinolin-2(1H)-one
- 1-(4-(5-Cyclohexyl-1H-Tetrazol-1-Yl)Butyl)-6-(4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy)-3,4-Dihydroquinolin-2(1H)-One
Cilostazol Related Compound C (1-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one)
CAS:Lactams, nesoiFormula:C31H45N9O2Colore e forma:White PowderPeso molecolare:575.369621-(4-(5-Cyclohexyl-1H-tetrazol-1-yl)butyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
CAS:Prodotto controllatoFormula:C31H45N9O2Colore e forma:Colourless To Off-WhitePeso molecolare:575.75Ref: 4Z-C-079
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butyl]-3,4-dihydro-2(1H)-quinolinone
CAS:Prodotto controllatoImpurity Cilostazol USP Related Compound C
Applications 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butyl]-3,4-dihydro-2(1H)-quinolinone, is an impurity of Cilostazol (C441500), a potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake.
References Suri, A., et al.: J. Clin. Pharmacol., 38, 144 (1998), Park, S.-W., et al.: Am. J. Cardiol., 84, 511 (1999), Tsuchikane, E., et al.: Circulation, 100, 21 (1999);Formula:C31H45N9O2Colore e forma:NeatPeso molecolare:575.75Cilostazol Related Compound C
CAS:Cilostazol is a drug that is used to treat the symptoms of intermittent claudication. It is a quinone-type inorganic base, obtained by the hydration of cilostazol. Cilostazol is an inhibitor of phosphodiesterase type 3 (PDE3) and has been shown to inhibit platelet aggregation, which may be due to its ability to inhibit PDE3 and prevent the breakdown of cyclic guanosine monophosphate (cGMP).
Formula:C31H45N9O2Purezza:Min. 95%Colore e forma:PowderPeso molecolare:575.75 g/mol6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butyl]-3,4-dihydro-2(1H)-quinolinone-d11
CAS:Prodotto controllatoFormula:C31D11H34N9O2Colore e forma:NeatPeso molecolare:586.816Ref: ST-EA-CP-C6003
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta





